Skip to main content
. Author manuscript; available in PMC: 2017 Dec 7.
Published in final edited form as: Lancet Oncol. 2014 Feb 17;15(3):286–296. doi: 10.1016/S1470-2045(14)70030-0

Figure 3.

Figure 3

Best percentage change from baseline.

Excludes one dovitinib patient who had 170% increase from baseline and 48 dovitinib and 60 sorafenib patients who had percentage changes in target lesions that were contradicted by overall lesion response of disease progression.